Session Details

Session Details

01:30 PM - 03:15 PM - Ballroom 1

Giuliana Ferrari - PhD - HSR-TIGET, Fondazione S. Raffaele

Co-Chair

01:30 PM - 03:15 PM - Ballroom 1

John Tisdale - MD - NIH, NHLBI

Co-Chair

01:30 PM - 01:45 PM - Ballroom 1

Alok Srivastava - MD - Christian Medical College Vellore

240: FVIII Expression through Autologous CD34+ Hematopoietic Stem Cells Transduced with a Lentiviral Vector with a Novel F8 Transgene for Gene Therapy of Hemophilia A - A First-in-Human Clinical Trial

01:45 PM - 02:00 PM - Ballroom 1

Christopher Jewell - PhD - Cartesian Therapeutics

241: Investigation of mRNA Cell Therapy as a Treatment for Autoimmune Disease in Patients with Myastenia Gravis

02:00 PM - 02:15 PM - Ballroom 1

Claire Henchcliffe - MD, DPhil - University of California, Irvine

242: Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months from a Phase 1 Study

02:15 PM - 02:30 PM - Ballroom 1

Che-Hsing Li - MD - Baylor College of Medicine–Texas Children’s Hospital–Houston Methodist Hospital

243: Eighteen-Year Follow-Up of GD2 Chimeric Antigen Receptor-Cytotoxic T Lymphocyte Therapy in Patients with Neuroblastoma

02:30 PM - 02:45 PM - Ballroom 1

Biao Zheng - MD, PhD - BRL Medicine Inc.

244: Efficacy and Safety of BRL-101, CRISPR-Cas9-Mediated Gene Editing of The BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

02:45 PM - 03:00 PM - Ballroom 1

Agnieszka Czechowicz - MD, PhD - Ctr for Definitive and Curative Med, Stanford Univ

245: Lentiviral-Mediated Gene Therapy (RP-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Patterns in the Absence of Conditioning

03:00 PM - 03:15 PM - Ballroom 1

Donald Kohn - Dept Pediatrics, Univ of California

246: Autologous Ex-Vivo Lentiviral Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I Provides Sustained Efficacy with a Favorable Safety Profile